JPRN-UMIN000050247已完成Unknown
Real-world experience of venetoclax for patients with newly diagnosed acute myeloid leukemia in Japan: a Multicenter Observational Study - VENUS study
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- AbbVie GK
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients who explicitly declines the use of data for this study. 2.Patients who received prior lines of therapy for AML. (Note that patients treated with AZA for MDS will be included in this study)
研究者
相似试验
招募中
1 期
A phase Ib clinical evaluation of Venetoclax in combination with chemotherapy in older patients with Acute Myeloid LeukemiaAcute myeloid leukaemiaCancer - Leukaemia - Acute leukaemiaACTRN12616000445471Alfred Health48
招募中
2 期
A phase 2 study of venetoclax in combination with low-dose cytarabine in relapsing acute myeloid leukemiaCancer - Leukaemia - Acute leukaemiaAcute Myeloid LeukemiaACTRN12619000746134Alfred Hospital32
招募中
1 期
Multicenter, Phase 3 Study of Venetoclax and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional ChemotherapyAcute Myeloid Leukemia in First RemissionMedDRA version: 21.0Level: PTClassification code: 10000881Term: Acute myeloid leukaemia (in remission) Class: 100000004864CTIS2023-507221-42-00AbbVie Deutschland GmbH & Co. KG122
进行中（未招募）
1 期
Multicenter, Phase 3 Study of Venetoclax and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional ChemotherapyAcute Myeloid Leukemia (AML)EUCTR2019-002217-19-GRAbbVie Deutschland GmbH & Co. KG112
进行中（未招募）
1 期
Multicenter, Phase 3 Study of Venetoclax and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional ChemotherapyAcute Myeloid Leukemia (AML)EUCTR2019-002217-19-DEAbbVie Deutschland GmbH & Co. KG112